Foubert
Daniel N. Foubert, Maricopa, AZ US
Patent application number | Description | Published |
---|---|---|
20130241180 | STRUCTURE MOUNTED AIRBAG ASSEMBLIES AND ASSOCIATED SYSTEMS AND METHODS - Structure mounted airbag assemblies and associated systems and methods are described herein. An airbag system configured in accordance with an embodiment of the present disclosure can include, for example, a housing having a cavity and an opening in communication with the cavity, an airbag assembly within the cavity, and an inflator operably coupled to the airbag assembly. The airbag assembly can include an airbag configured to deploy through the opening of the housing during a crash event. The airbag system can further include a door removably positioned across the opening and configured to move away from the opening during airbag deployment. The housing can be affixed to an interior portion of an aircraft, forward of and offset from an aircraft seat. | 09-19-2013 |
Daniel Nick Foubert, Maricopa, AZ US
Patent application number | Description | Published |
---|---|---|
20090236828 | INFLATABLE PERSONAL RESTRAINT SYSTEMS HAVING WEB-MOUNTED INFLATORS AND ASSOCIATED METHODS OF USE AND MANUFACTURE - Inflatable restraint systems for restraining an occupant in a vehicle are disclosed herein. An inflatable restraint system configured in accordance with one embodiment of the invention includes an airbag carried by a web. The web has an end portion coupled to a vehicle and is configured to extend around a portion of the occupant. The restraint system further includes a gas source that is also carried by the web. The gas source is operably coupled to the airbag to inflate the airbag in the event of a rapid deceleration or other dynamic event. | 09-24-2009 |
20100115737 | BUCKLES FOR INFLATABLE PERSONAL RESTRAINT SYSTEMS AND ASSOCIATED SYSTEMS AND METHODS - Buckles for inflatable personal restraint systems and associated systems and methods. In one embodiment, a buckle assembly can include a body and a latching mechanism carried by the body. The latching mechanism is configured to engage a corresponding tongue portion when the tongue is inserted into a front portion of the body. The buckle assembly also includes a cover operably coupled to the body and configured to pivotably move about an axis between a first position in which the latching mechanism engages the tongue and a second position in which the latching mechanism disengages the tongue. The buckle assembly further includes one or more counterweight components carried by the body and positioned such that the buckle assembly has a center of gravity (a) between the front portion of the body and a vertical plane extending through the axis, and (b) below a horizontal plane extending through the axis. | 05-13-2010 |
20150042078 | STRUCTURE MOUNTED AIRBAG ASSEMBLIES AND ASSOCIATED SYSTEMS AND METHODS - Structure mounted airbag assemblies and associated systems and methods are described herein. An airbag system configured in accordance with an embodiment of the present disclosure can include, for example, a housing having a cavity and an opening in communication with the cavity, an airbag assembly within the cavity, and an inflator operably coupled to the airbag assembly. The airbag assembly can include an airbag configured to deploy through the opening of the housing during a crash event. The airbag system can further include a door removably positioned across the opening and configured to move away from the opening during airbag deployment. The housing can be affixed to an interior portion of an aircraft, forward of and offset from an aircraft seat. | 02-12-2015 |
Philippe Foubert, La Garde FR
Patent application number | Description | Published |
---|---|---|
20100086524 | CELLULAR PREPARATIONS FOR USE AS A REVASCULARIZATION STIMULATING AGENT - The invention relates to a cellular preparation containing endothelial cell precursors (EPCs) and smooth muscular cell precursors (SMCs), as a combination product for simultaneous, separated or time-spread administration, used as a revascularisation stimulating agent. The invention also relates to the use of such a cellular preparation. | 04-08-2010 |
Philippe Foubert, Charenton Le Pont FR
Patent application number | Description | Published |
---|---|---|
20090123431 | CELL/LIGAND MARKING SYSTEM, WHEREIN THE MARKER IS OF EPH TYPE, CELL MATERIAL COMPRISING SAID SYSTEM, METHOD FOR PREPARING SAME AND PROANGIOGENETIC USE - A cell/ligand specific marking system, the system being characterized in that it comprises: (a) an endothelial precursor cell (EPC) including a cell marker selected from among the group consisting of the Eph (in particular EphB4 or EphB1), and (b) a protein material of structure L-K, which consists of a ligand (L) specific of the marker and is associated or fused with a binding protein (K), the system being capable of providing a proangiogenetic cell material of structure EPC-Eph-L-K. The invention also concerns the cell material as product capable of stimulating angiogenesis, its preparation method and its therapeutic use, in particular with respect to vascular insufficiencies. | 05-14-2009 |
Thomas R. Foubert, Bozeman, MT US
Patent application number | Description | Published |
---|---|---|
20080299152 | Norovirus Vaccine Formulations - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 12-04-2008 |
20100150961 | VIRUS LIKE PARTICLE PURIFICATION - Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses. | 06-17-2010 |
20100266636 | METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS - The present invention relates to vaccine compositions comprising | 10-21-2010 |
20110182975 | METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS - The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject. | 07-28-2011 |
20120093861 | NOROVIRUS VACCINE FORMULATIONS - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 04-19-2012 |
20120156243 | NOROVIRUS VACCINE FORMULATIONS - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 06-21-2012 |
20130273102 | PARENTERAL NOROVIRUS VACCINE FORMULATIONS - The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed. | 10-17-2013 |
20130273105 | NOROVIRUS VACCINE FORMULATIONS - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 10-17-2013 |
20130273147 | METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS - The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject. | 10-17-2013 |
20130273148 | NOROVIRUS VACCINE FORMULATIONS - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 10-17-2013 |
20130344107 | VIRUS LIKE PARTICLE PURIFICATION - Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses. | 12-26-2013 |
20140286994 | NOROVIRUS VACCINE FORMULATIONS - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 09-25-2014 |
Tom Foubert, Sint-Niklaas BE
Patent application number | Description | Published |
---|---|---|
20120085151 | METHOD AND APPARATUS FOR CHARACTERIZING POLYMERS - The present invention relates to a method for automatically determining the relative solution viscosity and/or the melt volume flow rate of a polymer, during a phase of the process for producing the polymer, where the polymer is in a solution with 10 to 20% by weight of the polymer in an organic solvent. The method includes continuously removing a substream of the polymer solution from a component of the process for producing the polymer, wherein the polymer solution is essentially free from inorganic salts; removing a sample having a volume of from 1 to 10 μl from the substream; introducing the sample into a gel permeation chromatography apparatus and determining the gel permeation chromatography data for the polymer; and automatically determining the relative solution viscosity and/or the melt volume flow rate of the polymer from the data obtained from the gel permeation chromatogram, on the basis of calibration relationships. | 04-12-2012 |